Albania
Bośnia i Hercegowina
Bułgaria
Chorwacja
Cypr
Czarnogóra
Czechy
Dania
Estonia
Hiszpania
Kosowo
Litwa
Łotwa
Luksemburg
Macedonia
Niemcy
Polska
Portugalia
Rumunia
Serbia
Słowacja
Słowenia
Szwajcaria
Szwecja
Turcja
Węgry
Wielka Brytania
Włochy
UAE
Hong Kong
Kuwejt
Liban
RPA
Terapie
komórkami macierzystymi
Terapie komórkami macierzystymi
Celem bankowania komórek macierzystych jest ich późniejsze wykorzystanie w terapii. Krew pępowinowa została zastosowana po raz pierwszy w 1988 roku, a od tego czasu – zgodnie z dostępnymi danymi – komórki macierzyste zostały użyte na świecie ponad 85 000 razy (łącznie ze statystykami z Chin).
Grupa FamiCord przechowuje ponad 1 000 000 porcji komórek różnych typów i dostarczyła komórki macierzyste do zastosowań klinicznych dla ponad 7000 pacjentów. Dostarczamy komórki do standardowych przeszczepień (z krwi pępowinowej, szpiku kostnego i mobilizowanej krwi obwodowej) oraz do terapii komórkowych. Ponadto wytwarzamy produkty komórkowe w standardzie GMP (ang. Good Manufacturing Practice) do badań klinicznych.
Komórki macierzyste pochodzące z naszych laboratoriów były wykorzystywane w leczeniu pacjentów z chorobami i wskazaniami z różnych obszarów terapeutycznych – m.in. hematologii, neurologii, okulistyki, ortopedii i dermatologii.
Sprawdź pełną listę pacjentów, którzy otrzymali terapię komórkami macierzystymi pochodzącymi z laboratoriów Grupy FamiCord.
Data aktualizacji: 06.2026
Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord
| Lp. | Źródło | Typ źródła | Wskazanie | Obszar medycyny | Rok podania | Terapia | Kraj | Wiek odbiorcy |
|---|---|---|---|---|---|---|---|---|
| 1501 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 69 |
| 1502 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 70 |
| 1503 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 75 |
| 1504 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 56 |
| 1505 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 23 |
| 1506 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 54 |
| 1507 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 69 |
| 1508 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 70 |
| 1509 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 65 |
| 1510 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 48 |
| 1511 | Bone Marrow Family | Allogeneic | Acute Myeloid Leukemia | Hematology | 2024 | Standard Therapy | Germany | 72 |
| 1512 | Bone Marrow Family | Allogeneic | Chronic Lymphocytic Leukemia Richter Transformation | Hematology | 2024 | Standard Therapy | Poland | 55 |
| 1513 | Bone Marrow Family | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 63 |
| 1514 | Bone Marrow Family | Allogeneic | Follicular Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 48 |
| 1515 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 65 |
| 1516 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Germany | 58 |
| 1517 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 70 |
| 1518 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome – Refractory Cytopenia Of Childhood | Hematology | 2024 | Standard Therapy | Poland | 14 |
| 1519 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome/ Myeloproliferative Neoplasms | Hematology | 2024 | Standard Therapy | Germany | 61 |
| 1520 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome-MPN | Hematology | 2024 | Standard Therapy | Poland | 71 |
| 1521 | Bone Marrow Family | Allogeneic | Myelofibrosis | Hematology | 2024 | Standard Therapy | Poland | 68 |
| 1522 | Bone Marrow Family | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 64 |
| 1523 | Bone Marrow Family | Allogeneic | Polycythemia Vera/Myelofibrosis | Hematology | 2024 | Standard Therapy | Poland | 74 |
| 1524 | Bone Marrow Family | Allogeneic | Primary Myelofibrosis | Hematology | 2024 | Standard Therapy | Germany | 62 |
| 1525 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 68 |
| 1526 | Bone Marrow Family | Allogeneic | Myelodysplasia | Hematology | 2024 | Standard Therapy | United Kingdom | 57 |
| 1527 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Germany | 69 |
| 1528 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | USA | 58 |
| 1529 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | USA | 60 |
| 1530 | Bone Marrow Family | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 71 |
| 1531 | Bone Marrow Family | Allogeneic | High risk Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Germany | 69 |
| 1532 | Bone Marrow Family | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | USA | 74 |
| 1533 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 15 |
| 1534 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 8 |
| 1535 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 12 |
| 1536 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 8 |
| 1537 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 52 |
| 1538 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 57 |
| 1539 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 66 |
| 1540 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 5 |
| 1541 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 54 |
| 1542 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 56 |
| 1543 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 3 |
| 1544 | Bone Marrow | Allogeneic | Adrenoleukodystrophy | Hematology | 2024 | Standard Therapy | Poland | 7 |
| 1545 | Bone Marrow | Allogeneic | Adrenoleukodystrophy | Hematology | 2024 | Standard Therapy | Poland | 7 |
| 1546 | Bone Marrow | Allogeneic | Adrenoleukodystrophy | Hematology | 2024 | Standard Therapy | Poland | 9 |
| 1547 | Bone Marrow | Allogeneic | B-Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 7 |
| 1548 | Bone Marrow | Allogeneic | Chronic Granulomatous Disease | Hematology | 2024 | Standard Therapy | Poland | 4 |
| 1549 | Bone Marrow | Allogeneic | Chronic Granulomatous Disease | Hematology | 2024 | Standard Therapy | Poland | 41 |
| 1550 | Bone Marrow | Allogeneic | Chronic Lymphocytic Leukemia Richter Transformation | Hematology | 2024 | Standard Therapy | Poland | 55 |
| 1551 | Bone Marrow | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 67 |
| 1552 | Bone Marrow | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 12 |
| 1553 | Bone Marrow | Allogeneic | Diffuse Large B-Cell Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 61 |
| 1554 | Bone Marrow | Allogeneic | Genetically Determined Thrombocytopenia | Hematology | 2024 | Standard Therapy | Poland | 4 |
| 1555 | Bone Marrow | Allogeneic | High Risk Acute Myeloid Leukaemia | Hematology | 2024 | Standard Therapy | Poland | 13 |
| 1556 | Bone Marrow | Allogeneic | Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 32 |
| 1557 | Bone Marrow | Allogeneic | Inherited Metabolic Disease | Hematology | 2024 | Standard Therapy | Poland | 11 |
| 1558 | Bone Marrow | Allogeneic | Mds-Rcc Relapse | Hematology | 2024 | Standard Therapy | Poland | 14 |
| 1559 | Bone Marrow | Allogeneic | Mixed Cellularity Hodgkin Lymphoma | Hematology | 2024 | Standard Therapy | Poland | 43 |
| 1560 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 14 |
| 1561 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 8 |
| 1562 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 14 |
| 1563 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 67 |
| 1564 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 9 |
| 1565 | Bone Marrow | Allogeneic | Osteopetrosis type B | Hematology | 2024 | Standard Therapy | Poland | 13 |
| 1566 | Bone Marrow | Allogeneic | Other Leukemia | Hematology | 2024 | Standard Therapy | Poland | 9 |
| 1567 | Bone Marrow | Allogeneic | Primary Immunodeficiency | Hematology | 2024 | Standard Therapy | Poland | 7 |
| 1568 | Bone Marrow | Allogeneic | Primary Immunodeficiency Xlp-1 | Hematology | 2024 | Standard Therapy | Poland | 18 |
| 1569 | Bone Marrow | Allogeneic | Relapse T-Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Poland | 12 |
| 1570 | Bone Marrow | Allogeneic | Secondary Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 4 |
| 1571 | Bone Marrow | Allogeneic | Secondary Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 15 |
| 1572 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 7 |
| 1573 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 3 |
| 1574 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 10 |
| 1575 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 21 |
| 1576 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 18 |
| 1577 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 49 |
| 1578 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 16 |
| 1579 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 24 |
| 1580 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 13 |
| 1581 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 14 |
| 1582 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 21 |
| 1583 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Poland | 7 |
| 1584 | Bone Marrow | Allogeneic | Severe Combined Immunodeficiency | Hematology | 2024 | Standard Therapy | Poland | 2 |
| 1585 | Bone Marrow | Allogeneic | Severe Congenital Neutropenia | Hematology | 2024 | Standard Therapy | Poland | 1 |
| 1586 | Bone Marrow | Allogeneic | Shwachman-Diamond Syndrome | Hematology | 2024 | Standard Therapy | Poland | 10 |
| 1587 | Bone Marrow | Allogeneic | Sickle Cell Disease | Hematology | 2024 | Standard Therapy | Poland | 9 |
| 1588 | Bone Marrow | Allogeneic | Biphenotypic Acute Leukemia | Hematology | 2024 | Standard Therapy | Ukraine | 10 |
| 1589 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Poland | 58 |
| 1590 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | United Kingdom | 12 |
| 1591 | Bone Marrow | Allogeneic | hemophagocytic lymphohistiocytosis | Hematology | 2024 | Standard Therapy | Sweden | 4 |
| 1592 | Bone Marrow | Allogeneic | Severe combined immunodeficiency | Hematology | 2024 | Standard Therapy | Germany | 1 |
| 1593 | Bone Marrow | Allogeneic | Beta-Thalassemia Major | Hematology | 2024 | Standard Therapy | India | 11 |
| 1594 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Austria | 4 |
| 1595 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2024 | Standard Therapy | Norway | 33 |
| 1596 | Bone Marrow | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Spain | 16 |
| 1597 | Bone Marrow | Allogeneic | Severe Aplastic Anemia | Hematology | 2024 | Standard Therapy | Switzerland | 5 |
| 1598 | Bone Marrow | Allogeneic | T- Acute Lymphoblastic Leukemia | Hematology | 2024 | Standard Therapy | Ireland | 6 |
| 1599 | Bone Marrow | Allogeneic | Myelodysplastic Syndrome | Hematology | 2024 | Standard Therapy | Poland | 12 |
| 1600 | Bone Marrow | Allogeneic | Severe Combined Immunodeficiency | Hematology | 2024 | Standard Therapy | USA | 4 |